Studies related to Migraine and Feverfew

Efficacy And Safety Of 6.25 Mg T.i.d. Feverfew CO2-extract (MIG-99) In Migraine Prevention--a Randomized, Double-blind, Multicentre, Placebo-controlled Study

Effect Decrease
Trial Design Double blind
Trial Length n/a
Number of Subjects 170
Sex n/a
Notes for this study:
6.25mg of feverfew thrice a day was significantly better than placebo in reducing the occurrence of migraines, reducing an average of 4.76 attacks per month by 1.9 in feverfew and 1.3 in placebo; no significant side effects recorded

Full details on all 5 studies are available to Examine Members. Try out the Examine Membership with a 14-day free trial.

Already a Member? Log in now to access.